This is great to hear, and I doubt too many folks on here need a note of caution in this area. But perhaps it’ll be useful for someone. With respect to immune response to vaccines, including the wonderful mRNA vaccines, responses are very variable, so one person’s case is mostly relevant for that person, and not applicable to everybody. In this case, while the literature I’ve seen supports expectation of strong vaccine response in solid tumor patients, there are LOTS of variables. For example, antibody level indicators alone may not establish optimal or sufficient protection, protective levels of response may vary with the emergence of new variants (e.g., the currently dominant Delta variant, which is far more infectious than previous versions), will definitely vary by individual, may vary by type and stage of chemo, and may wane over time (or may not). We also won’t always see new, more vaccine-evasive variants until they are at least somewhat dispersed. In other words, this is a hopeful story, but I at least would urge continued caution in a community like this one until and unless vaccination levels increase in the general population (thus reducing community spread to lower levels).
7/19: Rectal cancer: Initially staged as IIIA, T2N1M0
Initially approx 4.25 cm, low/mid rectum, mod. well diff. adenocarcinoma
8/22 -10/14 4 rounds FOLFOX neoadjuvant, 3 w/Oxiplatin (lots of side effects/reduced size est. 70-75%)
neoadjuvant chemorad 11/19
4 rounds of FOLFOX July-August 2020
ncCR found 10/20; multiple biopsies negative
TAE 11/20, small amount of tumor removed, lung nodules orig id’d 6/20 stable Nov 2020
Chest CT 3/30/21 small growth in 2 nodules (3 and 5mm)
Stable in 6/28 scan.